See Why RenovoRx Stock Is Shooting Higher On Tuesday

The FDA has granted a new 510(k) clearance to RenovoRx Inc's RNXT RenovoCath Delivery System.
The RenovoCath Delivery System is the device component of the Company's initial product, RenovoGem.
The drug/device combination used in RenovoRx's Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform is a dual-balloon infusion catheter delivering chemotherapy directly to tumors via arteries.
The new design provides more targeted therapy delivery, translating into more effective treatment with fewer side effects.
RenovoRx received it's initial 510(k) for the RenovoCath delivery system in 2014.
RenovoRx is conducting a Phase 3 trial utilizing the RenovoTAMP platform to evaluate RenovoGem in pancreatic cancer.
The study has reached 44% patient enrollment and is expected to involve approximately 200 participants.
Related content: Benzinga's Full FDA Calendar.
Price Action: RNXT shares are up 64.9% at $13.01 during the premarket session on the last check Tuesday.